1
29 2 28
1
1
1
1
1
2
1.
BZBZ-GABA
A-BZ GABAA
36 3
BZ
BZ
2013; 16(6): 803-812, Modern Physician 2014; 34(6): 653-656
2010
BZ
Report of International Narcotics Control Board for 2010. suppl.1, 2010, 40
24 26 3
28 9 14
306 30 28 10 13
365
1960 BZ
2015; 66(12): 2949-2954
1980 BZ
2015; 66(12): 2949-2954
29 1 26
3
20 12 25 20 8
2.
1980 BZ
MHRA1988
BZ 24 12011 7
4 2
2012 9 ANSMBZ
4
12 3
1982 BZ BZ
24 12
BZ
2 4 4
2007
BZ 12 4
5
III
1 28 6 30
6
2
50 695 720
1 MHRA HP: Current Problems in Pharmacovigilance: Number 21 (pages 1-4) January 1988 2 MHRA HP: Addiction to benzodiazepines and codeine 3 ANSM HP: Plan dactions de lANSM visant rduire le msusage des benzodiazpines - Point d'information 4 Authority of The Minister of National Health and Welfare, The Effects of Tranquillization: Benzodiazepine Use in Canada, 1982 5 Danish Health Authority HP: Vejledning om ordination af afhngighedsskabende lgemidler og om substitutionsbehandling af personer med opioidafhngighed 6 MedDRASMQPT
4
171 179 158 163 126
129 118 121 64 74
BZ BA BA
15
17
2. 14
15 1
1 473
116 14 15 15 101
1 1 442
54 14
41 15 13 442
PT 369
2 2.1
2013; 28: 232-2367
BZ
BZ
BZ
2015; 66(12): 3003-30078
BZ
2 20%
2
BZ Benzodiazepine Dependence Self-Report Questionnaire
7 , , 2013; 28: 232-236 8 , BzRAs , 2015; 66(12): 3003-3007
5
Bendep-SRQ
2013; 24(8): 763-7719
BZ
GABA GABAA 1 BZ
GABA
2015; 66(12): 2949-295410
MHRA 1988 BZ BZ
BZ BZ
BZ
Progress in Medicine 2007; 27(10): 131-14011
diazepine 2 3 diazepam
BZ 1 4
BZ
barbiturate BZ
BZ
BZ BZ
BZ
2009; 67(8): 1585-158912
BA therapeutic window
therapeutic window BA
9 et al, , 2013; 24(8): 763-771 10 , , BzRAs , 2015; 66(12): 2949-2954 11 , tofisopam, TM, Progress in Medicine 2007; 27(10): 131-140 12 , , 2009; 67(8): 1585-1589
6
NEW ; 6: 348-35013
BA
2005; 82(5): 771-77414
BA
BA
2.2
2.2.1
15
40
Q1, 25, 34, 38, 39
A1 BZ BZ BA BA
A25
13 NEW ; 6: 348-350 14 , , , 2005; 82(5): 771-774 15 , , 2013
7
BZ BZ
A34
A38
A39
2.2.2.
. 201216
BZ
.DSM-5/ 201617
BZ
BZ 4
BZ
18
BZ BZ
16 , . 2012, 2012 17 , .DSM-5/ 2016, 2016 18 , , , 2008
8
BZ
BZ
19
GAD
BZ
BZ 2
2.2.3.
201020
BZ
25
21
3 3.1
1 15 1
15 1
14 15 1.
BZ BA BA
BZ
19 et al, GAD GAD , 2008; 11: 1571-1573 20 , 2010, , 2010 21 , , 2005; 23(3): 249-253
9
2
GABAA 1 BZ
BZ
GABAA 1
BZ
BZ BZ
BZ
BZ
2
BZ
BA BA
BA
BA
BA
10
BZ BA
BZ
BA
3.2
BZ BA BA
BZ
BZ
BZ
BA
BA
3.3
3.2
3.4
11
BZ
2008; 11(2): 253-259
BZ BA
BZ
BA
BA
BA
BZ BA
BZ
12
IV
3
13
1
0.4mg
0.8mg
11.2mg3
12.4mg34
10.4mg112
11.2mg
0.4mg
0.8mg
1mg
2mg
3mg
12mg
11mg
13mg12mg
1mg
2mg
1
114mg
124mg
112mg
14
0.25mg
0.5mg
1mg 1
3mg3
1.5mg3
13mg
1
11.5mg
5
10 10
1. 11020mg13
2. 1
2mg/kg
15
15
20
1.
2.
1.
120mg
130mg
2.
115
30mg
130mg
1
2 1%
1. 1312mg3
2.
0.10.2mg/kg
5mg
10mg
10
11530mg13
1015mg
16
7.5mg
EPD
19
30mg24
124(
1530mg)24
5mg
10mg
1 10
1 2060mg 23
11020mg24
2mg
5mg 10mg
1
0.1
125mg124
1
15mg
31
15mg41212
10mg13
1
210mg134
1
510mg
2mg
5mg 1%
17
5mg
10mg
2mL10mg
34
2
10mg
7.5
10
1.
17.510mg
10mg
2.
17.510mg
10mg
18
5mg 10mg
1510mg
15mg
110mg
0.125mg
0.25mg
0.25 mg
0.5 mg
0.125 mg0.25 mg
0.25mg
0.5 mg
3mg
5mg
135mg
1%
5mg
10mg
1510mg
19
0.25mg
0.1
10.75mg3
4mg 1%
112mg3
2mg
124mg12
1
4mg
1mg 2mg
10.52mg
1
1mg
1
2
15
1.
2.
112
10
30mg
20
D
0.25mg
0.25mg
10.25mg
10.25mg
10.5mg
1
2 5
1
1615mg1
23
136mg1
23
5mg
21
0.5mg 1mg
0.1%
11.53mg3
11.5mg
2
5
11030mg
1mg
2mg
1.
2.
1.
11
2mg
12mg
2.
1
2mg
12mg
22
1% 1mg
2mg
Meiji Seika
2mg11
2
0.5 1.0
113mg23
1.0
112mg
12mg 1.0
0.5mg 1mg
2mg
0.1% 0.5%
(
BNS
10.5
1mg13
126mg13
11kg
0.025mg13
11kg0.1mg
13
0.5mg 1mg
2mg
0.1% 0.5%
23
5mg 10mg
1%
110mg
110
30mg13
140mg
10.2mg/kg
10.20.8mg/kg13
11.0mg/kg
4
6
10
10.40.5mg/kg11
2
1mg/kg
24
0.1
45
0.15mg/kg
1mg/
10.10.3mg/kg
0.6mg/kg
45
0.1mg/kg/
0.050.1mg/kg/
0.4mg/kg/
5mg
10mg
1%
1.
2.
3.
1.
1510mg
2.
1510mg
3.
1515mg
2
5 10
1
25
10.1
0.3g
10.10.2g23
0.2
1
100200mg5%24mL
500mg
5%10mL
5%14mL
50mg
150100mg
100200mg2100mg
12550mg1 23
26
10%
30mg
0.4%
130200mg1
4
1
30200mg
100mg
150200mg1
12
15 30
50
100
1.
2.
3.
47mg/kg
25 50
100
27
250mg
20mg/kg
2.55mg/kg
11
1520mg/kg11
114
D
E
F
1612
28
250mg
99.5
BNS
31250mg
3250mg
1
1,500mg23
12,000mg
31125mg
34125mg
23
2 250500mg
35 500750mg
615 7501,000mg
10%
112g
1020mL
2080mg/kg
0.20.8mL/kg2g
20mL
29
11
0.50.8g
1
0.61.0g3
250
500
3050mg/kg
1.5g
500
3050mg/kg
1.5g
50 10%
150mg13
30
MedDRA-PT version 19.0 2
MedDRA-PT
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 35 1 3 79 0 2 0 16 0 0 8 0 0 8 10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 0 2 0 0 4 0 0 0 1 0 0 0 0 0 0 2
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
60 0 10 340 0 0 4 55 0 0 11 0 20 67 66 9 0 1 118 0 0 3 15 0 0 6 0 0 1 18 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
35 0 2 65 1 0 3 6 1 0 3 0 2 35 27 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5 0 0 3 0 0 1 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 12 0 0 62 0 0 0 13 0 0 1 1 0 9 13 19 0 0 48 0 0 5 14 0 0 4 0 2 7 26 179 1 16 720 1 2 16 121 1 0 33 1 24 129 163
31
MedDRA-PT
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 2 5 0 4 5 0 0 0 30 17 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 7 0 10 2 0 0 0 20 8 0 0 0 0 0 0 0 0 3 1 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 1 6 0 11 4 2 0 0 8 10 22 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 4 0 10 0 0 0 0 0 1 0 0 0 0
